AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future Directions – UroToday
|
AUA 2018: Immunotherapy in Renal Cell Carcinoma: Current Standing and Future Directions
UroToday Dr. Campbell began by exploring the historical and present use of high dose Interleukin-2 (IL-2), as the initial form of immunotherapy used for renal cell carcinoma. The use of this drug helped to elucidate the fact that there are immune system factors … |
